Baclofen: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Dedupe migration per interface-claude 2026-05-20: Muscle Relaxants (CNS-acting) merged into canonical Muscle relaxants. Member retagged. |
MDElliottMD (talk | contribs) parser-claude: Baclofen MedTemplate refill, Top 300 stub upgrade |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic | | generic = Baclofen | ||
| brand | | brand = Lioresal (oral, intrathecal pump), Ozobax / Fleqsuvy (oral suspension), Gablofen (intrathecal), Lyvispah (oral granules) | ||
| structure | | structure = | ||
| classes | | classes = [[:Category:Skeletal muscle relaxants|Skeletal muscle relaxant (centrally-acting)]], [[:Category:Antispastics|Antispastic]], [[:Category:GABA-B receptor agonists|GABA-B receptor agonist]] | ||
| | | uses = <vote slug="spasticity-multiple-sclerosis-use">Spasticity in multiple sclerosis (FDA, oral and intrathecal)</vote>, <vote slug="spasticity-spinal-cord-injury-use">Spasticity in spinal cord injury (FDA, oral and intrathecal)</vote>, <vote slug="cerebral-palsy-spasticity-use">Cerebral palsy spasticity (FDA intrathecal; off-label oral)</vote>, <vote slug="alcohol-use-disorder-baclofen-use">Alcohol use disorder (off-label, evidence-supported, generally third-line)</vote>, <vote slug="persistent-hiccups-use">Persistent hiccups (off-label)</vote>, <vote slug="gerd-motility-use">GERD with esophageal motility dysfunction (off-label)</vote>, <vote slug="trigeminal-neuralgia-use">Trigeminal neuralgia adjunct (off-label)</vote> | ||
| uses | | starting_dose = Oral: 5 mg PO TID, titrate by 5 mg per dose every 3 days. Intrathecal: bolus test dose, then continuous infusion via implanted pump | ||
| starting_dose | | preparations = Tablets 5, 10, 20 mg; oral suspension 5 mg/5 mL (Ozobax, Fleqsuvy); intrathecal injection 50, 500, 1000, 2000 mcg/mL (Lioresal Intrathecal, Gablofen); oral granules (Lyvispah) | ||
| preparations | | fda_max = 80 mg/day oral (higher off-label) | ||
| fda_max = | | pill_id = | ||
| routes | | routes = Oral, intrathecal (via implanted infusion pump) | ||
| onset | | onset = 1-2 hours (oral) | ||
| duration | | duration = 4-6 hours (oral, TID-QID dosing) | ||
| halflife | | halflife = 3-4 hours<ref name="lioresal-label">FDA Prescribing Information, Lioresal (baclofen), Saol Therapeutics/Novartis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017851s019lbl.pdf</ref> | ||
| bioavailability = ~70-85% (oral)<ref name="lioresal-label" /> | |||
| pregnancy = Limited human data.{{citation needed}} | |||
| legal = [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance<ref name="lioresal-label" /> | |||
| | | mechanism = <vote slug="baclofen-mech-claim">Selective agonist at the GABA-B receptor (the only metabotropic GABA receptor; distinct from the ionotropic GABA-A targeted by benzodiazepines and Z-class hypnotics). Reduces excitatory neurotransmitter release presynaptically and hyperpolarizes postsynaptic membranes, producing antispastic effect particularly at spinal cord interneurons.</vote> '''Severe withdrawal syndrome''' is the marquee adverse-event concern, especially with abrupt cessation of intrathecal administration: hyperthermia, altered mental status, hyperreflexia, rhabdomyolysis, and multiorgan failure can develop within 24-72 hours and progress to death. Gradual taper is essential after extended use; intrathecal pump failures are a recognized emergency<ref name="lioresal-label" />. | ||
| | |||
| | |||
| | |||
| | |||
}} | }} | ||
== References == | |||
[[Category: | <references /> | ||
[[Category: | |||
[[Category: | [[Category:Skeletal muscle relaxants]] | ||
[[Category:Antispastics]] | |||
[[Category:GABA-B receptor agonists]] | |||